Status:
ACTIVE_NOT_RECRUITING
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Hepatocellular Carcinoma
Immunotherapy
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%\~70% in 5 years after surgery. Per...
Detailed Description
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%\~70% in 5 years after surgery. Per...
Eligibility Criteria
Inclusion
- Volunteer to participate in this study and sign an informed consent form
- Age 18\~75 years old, no gender limit
- Hepatocellular carcinoma confirmed by histopathology, cytology or imaging
- CNLC stage Ib/IIa/IIb/IIIa hepatocellular carcinoma, except for CNLC IIIa hepatocellular carcinoma combined with main portal vein tumor thrombus
- Child-Pugh score: A grade (≤6 points)
- ECOG PS score: 0-1 points
Exclusion
- Known intrahepatic cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and fibrolamellar cell carcinoma; have other active malignancies other than HCC within 5 years or at the same time.
- Currently accompanied by interstitial pneumonia or interstitial lung disease
- Existence of active autoimmune disease or history of autoimmune disease and may relapse
- Patients with active infection, unexplained fever ≥38.5℃ within 1 week before randomization, or baseline white blood cell count \>15\*10\^9/L
- Patients with congenital or acquired immune deficiencies (such as HIV-infected persons)
- Those who are known to be allergic to any monoclonal antibodies, anti-angiogenesis targeted drugs or excipients
Key Trial Info
Start Date :
March 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2026
Estimated Enrollment :
294 Patients enrolled
Trial Details
Trial ID
NCT04521153
Start Date
March 25 2021
End Date
March 1 2026
Last Update
May 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
180 Fenglin Road
Shanghai, Shanghai Municipality, China, 200032